RecruitingNCT06998329

PulmonAry hyperteNsion DiagnOsis: a National cohoRt reseArch

PANDORA: PulmonAry hyperteNsion DiagnOsis: a National cohoRt reseArch


Sponsor

University of Sao Paulo General Hospital

Enrollment

139 participants

Start Date

Jul 7, 2025

Study Type

OBSERVATIONAL

Summary

Understanding Delays in the Diagnosis of Pulmonary Arterial Hypertension and Rare Diseases in Brazil: A Multicenter Observational Study \--- Pulmonary arterial hypertension (PAH) is a rare, progressive, and life-threatening disease that affects the arteries of the lungs and the right side of the heart. Early diagnosis is essential to initiate appropriate treatment and improve patient outcomes. However, worldwide studies show that there is often a significant delay between the onset of symptoms and the final diagnosis. This delay may lead to disease progression and worse survival. This multicenter observational study aims to understand the time from the first symptoms to the diagnosis of PAH and other rare diseases across several Brazilian reference centers. By analyzing medical records and patient journeys, the investigators intends to identify factors contributing to delayed diagnosis and potential opportunities for earlier detection. The study includes adult patients diagnosed with PAH or other selected rare diseases within the last five years. The investigators will analyze time to diagnosis, number and type of physicians consulted, tests performed, and possible misdiagnoses. Our goal is to support the development of strategies that reduce diagnostic delay and improve access to specialized care for people living with rare diseases. This study does not involve any intervention and poses no additional risk to participants, as it is based solely on retrospective data from medical records.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This national cohort study in France examines how long it takes for people with pulmonary arterial hypertension (PAH) — a condition where the blood pressure in the lung arteries is too high — to receive a confirmed diagnosis after their first symptoms appear. The goal is to identify and reduce diagnostic delays. **You may be eligible if...** - You have a confirmed diagnosis of pulmonary arterial hypertension (Group 1 PAH) - Your diagnosis was confirmed by right heart catheterization (a specific cardiac test) - The date of your first symptoms and the date of your official diagnosis are both documented **You may NOT be eligible if...** - Your pulmonary hypertension is caused by left heart disease, chronic lung disease, or blood clots (Groups 2–5 PAH) - Your symptom onset or diagnosis date is unknown or undocumented - Your diagnosis was based only on echocardiography without a right heart catheterization Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERThere will be no intervention

There will be no intervention


Locations(1)

InCor - Universidade de São Paulo

São Paulo, São Paulo, Brazil

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06998329